It’s a dark time in the struggle with the coronavirus, particularly in the United States, where infections and hospitalizations have surged.
But amid the gloom comes some light: A trial by the drug maker Pfizer has returned preliminary results suggesting that its vaccine is 90 percent effective in preventing Covid-19.
With the virus raging, how strong is this new ray of hope?
Guest: Carl Zimmer, a science writer and author of the “Matter” column for The New York Times.
For more information on today’s episode, visit nytimes.com/thedaily
Background reading:
- Pfizer has announced positive early results from its coronavirus vaccine trial, cementing the lead in a frenzied global race that has unfolded at record-breaking speed.
- Meet the couple behind the German company, BioNTech, that partnered with Pfizer to develop the vaccine.